Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gunnar Hillerdal

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
The European Respiratory Journal|May 18, 2013
Slow-growing lung cancer as an emerging entity: from screening to clinical managementMaurizio Infante, Thierry Berghmans, Marjolein A Heuvelmans, et al.
Epidemiology and Health|November 22, 2016
Occupation and mesothelioma in Sweden: updated incidence in men and women in the 27 years after the asbestos banNils Plato, Jan Ivar Martinsen, Pär Sparén, et al.
Lung Cancer International|August 29, 2015
Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, SwedenHirsh Koyi, Gunnar Hillerdal, Olov Andersson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 4, 2008
Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II studyGunnar Hillerdal, Jens Benn Sorensen, Stein Sundström, et al.
Anticancer Research|November 1, 2016
Non-small Cell Lung Cancer (NSCLC) in Octogenarians in Clinical PracticeHirsh Koyi, Gunnar Hillerdal, Karl-Gustav Kölbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study GroupChrister Sederholm, Gunnar Hillerdal, Kristina Lamberg, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 14, 2008
Detection of Chlamydia pneumoniae on cytospin preparations from bronchoalveolar lavage in COPD patients and in lung tissue from advanced emphysemaEva Brandén, Judy Gnarpe, Gunnar Hillerdal, et al.
Plos One|August 31, 2013
Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesotheliomaFilip Mundt, Gustav Nilsonne, Sertaç Arslan, et al.
Health and Quality of Life Outcomes|October 5, 2013
Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study designRohit Lal, Nawel Bourayou, Gunnar Hillerdal, et al.
Oncotarget|November 16, 2017
<i>Ex vivo</i> evaluation of tumor cell specific drug responses in malignant pleural effusionsCarl-Olof Hillerdal, Rita Ötvös, Tünde Szatmári, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
The European Respiratory Journal|May 18, 2013
Slow-growing lung cancer as an emerging entity: from screening to clinical managementMaurizio Infante, Thierry Berghmans, Marjolein A Heuvelmans, et al.
Epidemiology and Health|November 22, 2016
Occupation and mesothelioma in Sweden: updated incidence in men and women in the 27 years after the asbestos banNils Plato, Jan Ivar Martinsen, Pär Sparén, et al.
Lung Cancer International|August 29, 2015
Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, SwedenHirsh Koyi, Gunnar Hillerdal, Olov Andersson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 4, 2008
Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II studyGunnar Hillerdal, Jens Benn Sorensen, Stein Sundström, et al.
Anticancer Research|November 1, 2016
Non-small Cell Lung Cancer (NSCLC) in Octogenarians in Clinical PracticeHirsh Koyi, Gunnar Hillerdal, Karl-Gustav Kölbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study GroupChrister Sederholm, Gunnar Hillerdal, Kristina Lamberg, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 14, 2008
Detection of Chlamydia pneumoniae on cytospin preparations from bronchoalveolar lavage in COPD patients and in lung tissue from advanced emphysemaEva Brandén, Judy Gnarpe, Gunnar Hillerdal, et al.
Plos One|August 31, 2013
Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesotheliomaFilip Mundt, Gustav Nilsonne, Sertaç Arslan, et al.
Health and Quality of Life Outcomes|October 5, 2013
Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study designRohit Lal, Nawel Bourayou, Gunnar Hillerdal, et al.
Oncotarget|November 16, 2017
<i>Ex vivo</i> evaluation of tumor cell specific drug responses in malignant pleural effusionsCarl-Olof Hillerdal, Rita Ötvös, Tünde Szatmári, et al.
Pageof 6